Trials / Available
AvailableNCT06877689
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
Expanded Access Protocol of Apitegromab for Patients With Spinal Muscular Atrophy
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Scholar Rock, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access program (EAP) is to provide access to apitegromab for eligible patients with spinal muscular atrophy (SMA) prior to approval by the local regulatory agency . A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apitegromab | Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion. |
Timeline
- First posted
- 2025-03-14
- Last updated
- 2025-03-14
Source: ClinicalTrials.gov record NCT06877689. Inclusion in this directory is not an endorsement.